Alice Shaw, MD, PhD | Authors


Efficacy Results for Lorlatinib in Patients With ALK-Positive NSCLC

May 04, 2018

Alice Shaw, MD, PhD, director of Thoracic Oncology at Massachusetts General Hospital, discussed the efficacy results from a recent trial investigating lorlatinib as treatment for patients with anaplastic lymphoma kinase-positive (ALK) non–small cell lung cancer that had failed other treatments prior, including crizotinib (Xalkori) and other multiple ALK tyrosine-kinase inhibitors.